Physician profile
Shawno E May
NPI 1922098276
$4,474.12
in general payments reported to CMS, 2019-2025
24 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $280 · 2021: $384 · 2022: $1,006 · 2023: $283 · 2024: $460 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.56 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,102.72 | 2019-2021 | |
| Rxsight INC | $389.45 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $387.23 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Regeneron Healthcare Solutions, INC. | $370.34 | 2019-2025 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $212.62 | 2020-2023 | |
| Genentech USA, INC. | $205.00 | 2022-2025 | Vabysmo |
| Abbvie INC. | $196.79 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $192.22 | 2023-2025 | Syfovre |
| Alcon Vision LLC | $173.16 | 2019-2024 | Hydrus Microstent |
| Glaukos Corporation | $144.11 | 2025 | Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $139.39 | 2019 | |
| Horizon Therapeutics Plc | $136.09 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $119.53 | 2019-2021 | |
| Amgen INC. | $116.34 | 2024 | Tepezza |
| Astellas Pharma US INC | $114.96 | 2023-2025 | Izervay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $111.71 | 2021 | |
| Allergan, INC. | $80.93 | 2019-2021 | |
| Eyepoint US, INC. | $59.67 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $46.34 | 2020-2025 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $38.01 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $36.40 | 2019 | |
| Dompe US, INC. | $33.33 | 2023-2025 | Oxervate |
| Shire North American Group INC | $28.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawno May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.